Clinical Trials in Barcelona, 2026

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Incyte Corporation

Phase 3

250

Alcorcón, Badalona, Barcelona, Esplugues de Llobregat, Madrid, Zaragoza

2025-11-13

Active, closed

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886Multiple Sclerosis

Hoffmann-La Roche

Phase 2

193

Las Palmas de Gran Canaria, EL Palmar (EL Palmar), Albacete, Alicante, Barcelona, Madrid, Seville

2025-11-13

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Barcelona, L Hospitalet Del Llobregat, Madrid, Seville

2025-11-13

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Santander, Barcelona, Madrid, Seville, Valencia

2025-11-12

Recruiting

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07023627Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 2

160

Barcelona, Córdoba, Girona, Madrid, Murcia, Valencia

2025-11-12

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

Badalona(Barcelona), Barcelona, Salamanca, Santander, Valencia

2025-11-12

Active, closed

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482Hyperlipidemia

DrugsEnlicitide·Enlicitide Decanoate·Rosuvastatin

Merck Sharp & Dohme LLC

Phase 3

996

Santiago de Compostela, Barcelona

2025-11-11

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Albacete, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz, El Palmar

2025-11-11

Recruiting

Does Hyaluronic Acid Help Relieve Dry Mouth?

NCT07594184Xerostomia

University of Barcelona

Not applicable

Barcelona

2025-11-11

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Barcelona, Fuenlabrada, Gijón, Madrid

2025-11-10

Recruiting

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration

ADARx Pharmaceuticals, Inc.

Phase 2

240

Barcelona, Madrid, Valencia

2025-11-10

Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)

DrugsObrixtamig·Etoposide·Atezolizumab·Carboplatin

Boehringer Ingelheim

Phase 3

670

A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca

2025-11-07

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Barcelona, Benalmádena, Madrid, Mérida, Patraix, Valencia

2025-11-06

Recruiting

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa

DrugBimekizumab

UCB Biopharma SRL

Phase 1

Barcelona

2025-11-05

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza

2025-11-05

Recruiting

Effects of Staged Adapted Inclusions in Infant Cereals on Oral-motors Patterns of 6-24 Month-old Children

NCT07318506Healthy, Infant and Young Child Feeding

Société des Produits Nestlé (SPN)

Not applicable

153

Barcelona, Valencia

2025-11-05

Recruiting

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Córdoba, Donostia / San Sebastian, Majadahonda, Asturias, Seville, Barcelona, Madrid, Valencia

2025-11-05

Recruiting

Characterization of Type 1 Diabetes Subgroup: An Artificial Intelligence Analysis of Clinical and Glucometric Features

NCT07461805Type 1 Diabetes Mellitus

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

800

Barcelona

2025-11-04

Recruiting

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122Haematologic Neoplasms

AstraZeneca

Phase 1

Barcelona, Madrid, Pamplona, Salamanca, Valencia

2025-11-03

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Seville

2025-11-03

Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure

Takeda

Observational

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-03

Recruiting

Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation

NCT07273994Persistent Atrial Fibrillation

DrugAmiodarone Hydrochloride

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 4

312

Barcelona

2025-11-01

Not yet open

Functional Improvement in Subacute/Chronic Stroke Through Non-invasive Virtual-reality-Based Telerehabilitation

NCT07240948Stroke

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

322

Barcelona

2025-11

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

Recruiting

A Study With CIT-013 in HS Patients

NCT06993233Hidradenitis Suppurativa (HS)

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-31

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Badajoz, Barcelona, Córdoba, Madrid, Murcia, Pamplona, Sabadell, Valencia

2025-10-30

Recruiting

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051Bronchiectasis

DrugGSK3862995B

GlaxoSmithKline

Phase 2

363

Barcelona, Lleida, Madrid, MErida Badajoz, Oviedo, Valencia

2025-10-30

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

A Coruña, Barcelona, Granada, Madrid, Seville, Valencia

2025-10-30

Active, closed

Pharmacokinetic Assessment of Betaine Supplementation in Lactating Mothers

NCT07243678Breast Milk Fortifier Supplements

Fundació Sant Joan de Déu

Not applicable

Barcelona

2025-10-30

Recruiting

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615Chronic Spontaneous Urticaria

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 2

200

Santiago de Compostela, Córdoba, Barcelona, Alcorcón, Valencia

2025-10-30

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)

DrugAvacincaptad Pegol

ONL Therapeutics

Phase 2

324

Barcelona, Bilbao, Córdoba, Madrid, Seville, Valencia, Zaragoza

2025-10-28

Recruiting

PKB171 Against Placebo in Couples With Mild Male Factor Infertility

NCT07669584Infertility Due to Azoospermia

Prokrea BCN, S.L.

Phase 2/3

732

Pamplona, Barcelona, Madrid, Seville

2025-10-28

Recruiting

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

NCT07377045Pancreatic Adenocarcinoma Metastatic

DrugsOMTX705·Nab-paclitaxel·Tislelizumab·Gemcitabine

Oncomatryx Biopharma S.L.

Phase 1

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Pamplona, Santiago de Compostela

2025-10-28

By invitation

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure

Praxis Precision Medicines

Phase 3

700

Barcelona, Madrid, Málaga, Terrassa, Valencia

2025-10-27

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962Immune Thrombocytopenia

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Sanofi

Phase 3

Barcelona, Burgos, Madrid, Murcia, San Cristóbal de La Laguna, Seville

2025-10-24

Recruiting

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville

2025-10-24

Recruiting

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

NCT07218887BAG3 Mutation Associated Dilated Cardiomyopathy

Alexion Pharmaceuticals, Inc.

Phase 1/2

Barcelona, Majadahonda

2025-10-24

Recruiting

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

NCT06899126Non-small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

686

A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga

2025-10-24

Recruiting

Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions

NCT06736899Coronary Artery Disease, Coronary Disease

Fundación EPIC

Not applicable

200

Alicante, Barcelona, Córdoba, Fuencarral-El Pardo, Lugo, Madrid, Salamanca, Seville

2025-10-23

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Barcelona, Madrid, Málaga, Salamanca, Valencia

2025-10-23

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Madrid, Seville, Zaragoza

2025-10-23

Recruiting

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

NCT07168434IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms

DrugSaccharomyces Boulardii

Biocodex

Phase 3

406

Barcelona, León, Madrid, Marbella, Málaga, Oviedo

2025-10-22

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo

2025-10-22

Recruiting

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

NCT07251413Cutaneous Basal Cell Carcinoma

DrugsImiquimod·Cemiplimab

Instituto Oncológico Dr Rosell

Phase 1/2

Barcelona, Madrid, Zaragoza

2025-10-22

Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor

Zymeworks BC Inc.

Phase 1

140

Barcelona, Logroño, Madrid, Málaga, Pamplona

2025-10-21

Recruiting

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma

DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab

Gruppo Oncologico del Nord-Ovest

Phase 2

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2025-10-20

Recruiting

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura

DrugEfgartigimod

argenx

Phase 2/3

Barcelona, Esplugues de Llobregat, Madrid

2025-10-20

Recruiting

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

1,196

Barcelona, Málaga, Palma de Mallorca

2025-10-20

Recruiting

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT07213609Neoplasms, Colorectal, Neoplasms

GlaxoSmithKline

Phase 1/2

Barcelona, Madrid

2025-10-20

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra

2025-10-15

Recruiting

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT07214727Alzheimer's Disease

Alnylam Pharmaceuticals

Phase 1

Barcelona, Madrid, Sant Cugat del Vallès

2025-10-15

Recruiting

Integrating AI in Stroke Neurorehabilitation

NCT07138495Stroke

Eodyne Systems SL

Not applicable

192

Barcelona

2025-10-15

Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725Solid Tumours

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

540

Málaga, Badalona, Barcelona, Pamplona, Madrid

2025-10-15

Recruiting

Oscillometry and Machine Learning Approaches

NCT07447596Asthma COPD

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2025-10-15

Recruiting

A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies

NCT07231458Advanced Solid Tumors

DrugPembrolizumab

Abalos Therapeutics GmbH

Phase 1

Barcelona, Madrid

2025-10-14

Recruiting

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

NCT06712459Transformed Splenic Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

100

Barcelona

2025-10-13

Recruiting

Spanish Validation of a Psychosocial Needs Assessment for Adolescents and Young Adults With Cancer (AYA-POST)

NCT07240935AYA Cancer Patients

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

100

Barcelona

2025-10-10

Recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

140

Esplugues, A Coruña, Barcelona, Madrid

2025-10-09

Recruiting

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT07465848Lung Cancer (Diagnosis), Health Adult Subjects, Patient

Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)

Not applicable

1,200

Elche, Barcelona, Santander, Madrid, Oviedo, Toledo, Valencia

2025-10-08

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Badalona, Barcelona, A Coruña, Majadahonda, Valencia, Madrid, Seville

2025-10-08

Active, closed

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT07176390Arthritis, Rheumatoid

DrugsTulisokibart·Methotrexate

Merck Sharp & Dohme LLC

Phase 2

185

Sabadell, Santander, Santiago de Compostela, Barcelona

2025-10-08

Recruiting

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT07175285Systemic Lupus Erythematosus (SLE)

Bristol-Myers Squibb

Observational

223

Mérida, Barcelona

2025-10-08

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab·Visugromab RDE·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Jaén, Málaga, Seville, Barcelona, Santiago de Compostela, Girona, Logroño, Madrid

2025-10-07

Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106Breast Cancer

DrugsRGT-419B·Giredestrant·Abemaciclib

Genentech, Inc.

Phase 1/2

285

Barcelona, Madrid, Valencia

2025-10-07

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

Barcelona, A Coruña, Madrid, Vigo, Seville, El Palmar, Palma de Mallorca, Salamanca

2025-10-06

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Barcelona, Gijón, Girona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-03

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Barcelona, Madrid, Oviedo, Málaga

2025-10-03

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville

2025-10-03

Recruiting

THERAVEX Tissue Care Spray Plus for the Management of Cutaneous Wounds, Burns, and Chronic Ulcers

NCT07617961Chronic Wounds, Burns, Pressure Ulcer, Traumatic Wounds

Biointelligent Technology Systems SL

Observational

Barcelona

2025-10-02

Recruiting

Comprehensive Assessment of First Trimester Pregnancy Loss

NCT07293819Miscarriage in First Trimester

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

225

Barcelona

2025-10-02

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2025-10-02

Not yet open

Cultural Adaptation, Validation, and Evaluation of the Programme for Promotion of Healthy Affective-Sexual Behaviours in Adolescents (IYG)

NCT07208045Sexual Behavior, Sexually Transmitted Disease (STD), Condom Use, Adolescent Health

University of Seville

Not applicable

1,200

Barcelona

2025-10-01

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2025-10-01

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia

2025-10-01

Recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Barcelona, Madrid, Valencia

2025-10-01

Recruiting

The Effect of Aerobic and Resistance Training in Patients With Type 2 Diabetes on Vitamin D Treatment

NCT06081387Diabetes Mellitus, Type 2

University Ramon Llull

Not applicable

Barcelona

2025-10-01

By invitation

Improving Frailty in Patients With Stable Ischemic Heart Disease

NCT07373119Coronary Heart Disease

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Not applicable

Barcelona

2025-10-01

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Barcelona, Ferrol, Galdakao, Gijón, Girona, Madrid, Santiago de Compostela, Seville

2025-10-01

Recruiting

Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke

NCT07174505Acute Ischemic Stroke, Large Vessel Occlusion

Anaconda Biomed S.L.

Not applicable

Barcelona

2025-10-01

Recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory

DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone

Princess Maxima Center for Pediatric Oncology

Phase 1/2

Barcelona, Madrid, Valencia

2025-10-01

Not yet open

Immersive Functional Virtual Reality in People With Acquired Brain Injury and Unilateral Spatial Neglect

NCT07017140Acquired Brain Injury Including Stroke, Unilateral Spatial Neglect (USN), Stroke, Traumatic Brain Injury

University of Vic - Central University of Catalonia

Not applicable

Barcelona, Vic

2025-10-01

Recruiting

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

NCT07040774Genetic Disease, Immune Dysfunction, Neurological Diseases or Conditions, Autoimmune Diseases

Imagine Institute

Observational

500

Barcelona, Palma de Mallorca

2025-10-01

Not yet open

Pilot Study of tSCS for Improving Upper Limb Function in People With Multiple Sclerosis

NCT07152145Multiple Sclerosis

Parc de Salut Mar

Not applicable

Barcelona

2025-10

Not yet open

A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations

NCT07178717Colo-rectal Cancer

DrugEncorafenib

Vall d'Hebron Institute of Oncology

Phase 2

Barcelona

2025-10

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Barcelona, Córdoba, Elche, Lugo, Pamplona, Seville

2025-09-30

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Santander, Madrid, Valencia, Badajoz, Córdoba, Seville

2025-09-30

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid

2025-09-30

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Barcelona, Madrid, Pamplona, Seville, Valencia

2025-09-30

Not yet open

METRIKAMIND - Development of a Digital Mental Health Ecosystem for Workplace Environments

NCT06650176Depression Disorders, Anxiety

David Gallardo-Pujol

Observational

400

Barcelona

2025-09-30

Recruiting

Paramedian Incidence Angles in Spinal Anaesthesia

NCT07210892Anesthesia; Adverse Effect, Spinal and Epidural

Consorci Sanitari de Terrassa

Observational

Barcelona

2025-09-30

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

NCT07285590Mantle Cell Lymphoma (MCL)

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Marbella, Pamplona, Salamanca

2025-09-30

Recruiting

TLN-372 in Advanced KRAS Mutant Solid Tumors

NCT07204340KRAS Mutant Solid Tumors

DrugsCetuximab·Pembrolizumab

Treeline Biosciences, Inc.

Phase 1

270

Barcelona, Madrid

2025-09-29

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville

2025-09-29

Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

1,000

Barcelona, Madrid, Vigo, Valencia

2025-09-28

Recruiting

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor

Drug177Lu-edotreotide

ITM Solucin GmbH

Phase 1

Barcelona, Madrid

2025-09-26

Recruiting

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

NCT07190196Immunoglobulin G4 Related Disease

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Sanofi

Phase 3

124

Barcelona, Madrid

2025-09-26

Recruiting

NCT07290257Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis

DrugMaralixibat

Mirum Pharmaceuticals, Inc.

Phase 4

230

Barcelona, Madrid

2025-09-25

Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381HER2-positive Breast Cancer, Breast Cancer

DrugsZanidatamab·Pertuzumab·Trastuzumab·Docetaxel

Jazz Pharmaceuticals

Phase 2

125

Granada, Vigo, Barcelona, Madrid

2025-09-24

Recruiting

A Study of PHN-012 in Patients With Advanced Solid Tumors

NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer

Pheon Therapeutics

Phase 1

165

Barcelona, Madrid, Valencia

2025-09-23

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2025-09-22

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

A Coruña, Alcalá de Henares, Alicante, Antequera, Badajoz, Barcelona, Burjassot, Cadiz

2025-09-22

Recruiting

Adhesive Devices Versus Elastic Devices for Urinary Catheter Securement in Critically Ill Patients Experimental Study

NCT07093437Pressure Injuries, Pain, Catheter-Associated Urinary Tract Infection, Medical Device Site Injury

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

188

Barcelona

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid

2025-09-22

Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423Chronic Obstructive Pulmonary Disease

DrugDupilumab

Sanofi

Phase 4

218

Santander, Barcelona, Pozuelo de Alarcón, Oviedo, Madrid

2025-09-22

Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive

DrugGilteritinib

Astellas Pharma Global Development, Inc.

Phase 1

Barcelona, Madrid, Málaga

2025-09-22

By invitation

Post Market Study of Tutopatch In Craniotomy

NCT07118020Craniotomy

RTI Surgical

Observational

Barcelona

2025-09-21

Recruiting

Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength in Athletes With Patellar Tendinopathy

NCT07237867Patellar Tendinopathy / Jumpers Knee

Hospital Clinic of Barcelona

Not applicable

Barcelona

2025-09-20

Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787Primary Membranous Nephropathy

Alexion Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid, Seville, Toledo

2025-09-19

Recruiting

Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression

NCT07422519Depression - Major Depressive Disorder, Depression Disorder, Depression Chronic, Treatment-Resistant Major Depressive Disorder

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2025-09-18

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Sant Cugat del Vallès, Terrassa, Donostia / San Sebastian, Lleida, Pozuelo de Alarcón, Barcelona, Córdoba, Madrid

2025-09-17

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Zaragoza, Badalona, Santander, Barcelona, Madrid

2025-09-17

Recruiting

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.

Phase 2

240

Alicante, Barcelona, Málaga, Valencia

2025-09-17

Recruiting

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

NCT07176689Desmoid Tumor, Aggressive Fibromatosis

DrugNirogacestat

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 4

Barcelona, Madrid, Valencia, Zaragoza

2025-09-17

Recruiting

iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)

NCT05655390Suicide, Attempted, Functioning, Psychosocial, Cognition, Neuroimaging

Iria Grande

Not applicable

120

Barcelona, Madrid

2025-09-16

Active, closed

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06992609Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander

2025-09-15

Active, closed

Evaluating the Effectiveness of an Online Cognitive Behavioral Therapy Program for University Students With Depression and/or Anxiety

NCT07246239Anxiety and Depression

University Rovira i Virgili

Not applicable

108

Barcelona, Girona, Tarragona

2025-09-15

Not yet open

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients

NCT07153406Depressive Disorder

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

220

Pamplona, Barcelona, Palencia, Sabadell, Seville

2025-09-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Eli Lilly and Company

Phase 3

800

A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid

2025-09-15

Recruiting

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3

DrugsApitegromab·Nusinersen·Risdiplam

Scholar Rock, Inc.

Phase 2

Barcelona, Valencia

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2025-09-13

Recruiting

NCT06926868Breast Neoplasms

DrugsIza-bren·Nab-paclitaxel·Capecitabine·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

600

A Coruña, Elche, Barcelona, Hospitalet, Donostia / San Sebastian, Madrid, Málaga, Valencia

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

A Coruña, Barcelona, Cadiz, Castellon, Ferrol, Jerez de la Frontera, Madrid, Málaga

2025-09-10

Recruiting

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190Breast Cancer

DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole

Hoffmann-La Roche

Phase 2

120

Barcelona, Madrid, Salamanca, Seville, Valencia

2025-09-09

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Barcelona, Hospitalet, Madrid, Málaga, Seville, Valencia

2025-09-09

Recruiting

Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest

NCT07174986Out of Hospital Cardiac Arrest, Ventricular Fibrillation, Defibrillation, CPR

Gabriel Riva

Phase 2/3

916

Málaga, Bilbao, Barcelona, Madrid

2025-09-08

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville

2025-09-08

Recruiting

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737Mantle-cell Lymphoma

DrugsLisaftoclax·Acalabrutinib

AstraZeneca

Phase 2

A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Gijón, Madrid

2025-09-05

Recruiting

First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers

NCT07163403Lynch Syndrome

Fundacion Clinic per a la Recerca Biomédica

Phase 1

Barcelona

2025-09-04

Recruiting

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745Refractory Autoimmune Diseases

DrugsTocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

125

Barcelona, Madrid

2025-09-04

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Barcelona, Jerez de la Frontera, Madrid, Málaga

2025-09-02

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

A Coruña, Barcelona, Centelles, Córdoba, Ferrol, Granada, Huelva, Jaén

2025-09-02

Recruiting

Clinical Trial on Bowel Preparation Comparing Mannitol 100g to Plenvu Both in a Same Day Regimen (CLEARWAY)

NCT07465705Elective Colonoscopy

DrugMannitol

NTC srl

Phase 3

412

Barcelona

2025-09-02

Recruiting

A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

NCT06984627Graves' Disease

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Sanofi

Phase 2

Barcelona, Pamplona, Seville

2025-09-02

Recruiting

Sleep Disorders in Hypothalamic and Pituitary Damage

NCT07143266Hypopituitarism, Sleep Wake Disorders, Hypothalamic Diseases, Oxytocin Deficiency

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2025-09-01

Recruiting

Robotic vs Open Pancreatoduodenectomy

NCT06981273Pancreas Neoplasms

Hospital del Mar

Not applicable

120

Barcelona

2025-09-01

Recruiting

Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)

NCT07028827Myopia

DrugAtropine eye

Ocus Innovation Ireland Limited

Phase 3

234

Barcelona, Cadiz, Madrid

2025-09-01

Not yet open

SVC-isolation in Redo-AF Ablation With Isolated PV

NCT07112716Paroxysmal AF

Centro Medico Teknon

Not applicable

100

Barcelona

2025-09-01

Not yet open

A Novel Psychological Intervention for Adults With Bipolar Disorder and Attention Deficit Hyperactivity Disorder Comorbidity (VECTOR)

NCT07039903ADHD, BD

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2025-09-01

Active, closed

Long-term Sustainability of the Effects of Dog-Assisted Therapy in Children and Adolescents With Fetal Alcohol Spectrum Disorder: a 12-month Longitudinal Study

NCT07717190Fetal Alcohol Effect, Fetal Alcohol Syndrome, Fetal Alcohol Syndrome Disorders

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2025-09-01

Not yet open

Validation and Evaluation of the Mastication Function in Adults: The Functional Six-minute Mastication Test (F-6MMT).

NCT06298786Mastication Disorder, Fatigue, Temporomandibular Disorder, Orofacial Pain

Fundació Universitària del Bages

Observational

514

Manresa, Barcelona

2025-09

Not yet open

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

Federation Francophone de Cancerologie Digestive

Phase 2

300

Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Oviedo, Pamplona, Salamanca, San Carlos

2025-08-31

Recruiting

Effects of PERMISSive Lung-protective Ventilation on Outcome in Critically Ill Invasively Ventilated Patients

NCT07077174Mechanical Ventilation, Intensive Care (ICU)

Reinier de Graaf Groep

Not applicable

Barcelona

2025-08-31

Recruiting

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

NCT07038824Duchenne Muscular Dystrophy (DMD)

DrugENTR-601-45

Entrada Therapeutics, Inc.

Phase 1/2

Barcelona

2025-08-30

Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2

ADARx Pharmaceuticals, Inc.

Phase 3

Barcelona, Madrid

2025-08-28

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)

ADARx Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid, Seville

2025-08-28

Recruiting

Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors

NCT07128303Advanced Solid Tumor

DrugsPemetrexed·Carboplatin·Pembrolizumab

Gilead Sciences

Phase 1

476

Barcelona, Madrid

2025-08-28

Recruiting

Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy

NCT07678112Rheumatoid Arthritis (RA)

Francisco J. Blanco

Not applicable

184

A Coruña, Alava, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna

2025-08-28

Recruiting

NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine

BeOne Medicines

Phase 3

351

Barcelona, Pamplona, Valencia, Zaragoza

2025-08-27

Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

NCT07200908Chronic Hepatitis D Infection

DrugBulevirtide

Mirum Pharmaceuticals, Inc.

Phase 3

172

Almería, Barcelona, Madrid, Málaga, Santander, Vigo

2025-08-27

Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma

Alentis Therapeutics AG

Phase 1/2

180

Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia

2025-08-26

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

DrugsCapivasertib·Fulvestrant

Relay Therapeutics, Inc.

Phase 3

540

Badajoz, Badalona, Barcelona, Castellon, Cáceres, El Palmar, Girona, Huelva

2025-08-26

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321Invasive Mold Infections

DrugFosmanogepix

Basilea Pharmaceutica

Phase 3

234

Seville, Barcelona, Barakaldo, Madrid

2025-08-26

Recruiting

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)

One-carbon Therapeutics AB

Phase 1/2

Barcelona, Madrid

2025-08-22

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700Episodic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

990

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713Chronic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

780

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer

Pfizer

Phase 1

540

Barcelona, Madrid

2025-08-20

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Seville, Santander, Castilleja de la Cuesta, A Coruña, Ferrol, Malaga, Málaga, Barcelona

2025-08-19

Recruiting

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer

DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone

Astellas Pharma Global Development, Inc.

Phase 2

218

Barcelona, Madrid, Santiago de Compostela

2025-08-19

Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976Autoimmune Haemolytic Anaemia

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sanofi

Phase 3

Seville, Bizkaia, Barcelona, Majadahonda, Madrid

2025-08-18

Active, closed

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin

Amgen

Phase 3

350

Málaga, Barcelona, Majadahonda, Valencia, Madrid

2025-08-18

Recruiting

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT07196501Major Depressive Disorder

DrugNBI-1065845

Neurocrine Biosciences

Phase 3

550

Alcorcón, Barcelona

2025-08-18

Recruiting

Open-label Extension Study in Participants With Early Alzheimer's Disease

NCT07105709Alzheimer's Disease

GlaxoSmithKline

Phase 2

220

Barcelona

2025-08-14

Recruiting

NCT07070232Advanced Solid Tumor

DrugsBNT326·Paroxetine·Itraconazole·Pumitamig

BioNTech SE

Phase 1/2

1,438

Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Valencia

2025-08-12

Recruiting

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

NCT07099898Neoplasms, Lung

DrugsRis-Rez·Risvutatug rezetecan·Topotecan

GlaxoSmithKline

Phase 3

420

Barcelona, L'Hospitalet de Llobrega, Las Palmas de Gran Canar, Madrid, Santander

2025-08-11

Recruiting

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054Pancreatic Adenocarcinoma

DrugSotorasib

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Phase 1

Zaragoza, Barcelona, Santander, Córdoba, Donostia / San Sebastian, Madrid, Málaga, Pamplona

2025-08-08

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Barcelona, Madrid, Seville

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Santiago de Compostela, Seville, Esplugues de Llobregat, Bizkaia, Barcelona, Alcalá de Henares, Madrid, Pamplona

2025-08-06

Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms

Eli Lilly and Company

Phase 1

421

Barcelona, Madrid

2025-08-06

Active, closed

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865Respiratory Syncytial Virus Infections

GlaxoSmithKline

Phase 2

168

A Coruña, Barcelona, Córdoba, Madrid, Santander

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander

2025-08-06

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Barcelona, A Coruña, Madrid, Cadiz, Córdoba, Murcia, Seville, Valencia

2025-08-06

Recruiting

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

NCT06709339Polypoidal Choroidal Vasculopathy

DrugsVabysmo·Faricimab

Association for Innovation and Biomedical Research on Light and Image

Phase 4

120

Barcelona, Madrid, Oviedo, Valencia

2025-08-06

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Zaragoza

2025-08-05

Recruiting

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

NCT07075016Acute Myeloid Leukemia

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3

227

Barcelona, Girona, Valencia

2025-08-05

Active, closed

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

NCT07142811Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 2

100

Barcelona, Madrid, Valencia

2025-08-05

Recruiting

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458Refractory Metastatic Colorectal Cancer

DrugsMelphalan·Trifluridine/Tipiracil·Bevacizumab

Delcath Systems Inc.

Phase 2

Barcelona

2025-08-05

Recruiting

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236Large B Cell Lymphoma

DrugEpcoritamab

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Seville, Zaragoza, Palma de Mallorca, Burgos, Salamanca, Badalona, Barcelona, Cáceres

2025-08-04

Recruiting

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

NCT07139743Progressive Multiple Sclerosis

DrugObecabtagene autoleucel

Autolus Limited

Phase 1

Barcelona, Valencia

2025-08-04

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Barcelona, Madrid, Valencia

2025-08-03

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

A Coruña, Santiago de Compostela, Alcobendas, Madrid, Seville, Barcelona

2025-08-01

Recruiting

CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome

NCT07468461Camptodactyly, Arthropathy, Coxa Vara, Pericarditis

Meyer Children's Hospital IRCCS

Observational

Barcelona

2025-08-01

Recruiting

HOPE Against Cancer Recurrence in HCC

NCT06717919Liver Transplantation, HCC, Oncological Outcomes

Philipp Dutkowski

Phase 4

220

Barcelona

2025-08-01

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo

2025-08-01

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja

2025-08-01

Not yet open

ACE Acetabular Cup Spanish PMCF Study

NCT07115732Hip Disease

JRI Orthopaedics

Observational

120

Barcelona

2025-08

Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors

DrugsPanitumumab·Pembrolizumab

Amgen

Phase 1

434

Barcelona, Madrid

2025-07-31

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Barcelona, Zaragoza

2025-07-31

Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013Immune Thrombocytopenia (ITP)

DrugPirtobrutinib

Eli Lilly and Company

Phase 1/2

Barcelona, Burgos, Murcia, Pamplona

2025-07-30

Active, closed

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550Viral Hepatitis

DrugsTobevibart·Elebsiran·Bulevirtide

Vir Biotechnology, Inc.

Phase 3

150

Barcelona, Madrid, Santander

2025-07-30

Recruiting

Visible Abdominal Distension

NCT06369753Irritable Bowel Syndrome, Dyspepsia, Functional Bloating

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

100

Barcelona

2025-07-30

Recruiting

A Study With CIT-013 in RA Patients

NCT06567470Rheumatoid Arthritis

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

A Coruña, Barcelona, Madrid, Santander, Santiago de Compostela

2025-07-29

Active, closed

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365Type 1 Interferonopathies

Boehringer Ingelheim

Phase 1

Barcelona, Madrid, Seville

2025-07-29

Recruiting

PALACE: Cemiplimab Trial According to ctDNA Levels

NCT06917573Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer

DrugsCarboplatine·Cemiplimab·Paraplatin·Taxol

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, Girona

2025-07-29

Recruiting

Reframing Expectations About Aging - Physical Activity and Inclusive Reappraisal

NCT07113860Self-perceptions of Aging, Physical Activity

University of Barcelona

Not applicable

342

Barcelona

2025-07-28

Recruiting

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT07080905Hemophilia B

CSL Behring

Phase 3

Barcelona, Madrid

2025-07-28

Recruiting

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis

DrugsCisplatin·Carboplatin·Pembrolizumab

Eli Lilly and Company

Phase 1

240

Barcelona, Madrid

2025-07-28

Recruiting

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

DrugPanitumumab

Astellas Pharma Inc

Phase 1

364

Barcelona, Madrid

2025-07-25

Recruiting

Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

NCT07010159Pericarditis, Pericarditis Acute, Recurrent Pericarditis

DrugKPL-387

Kiniksa Pharmaceuticals International, plc

Phase 2/3

325

Barcelona, Madrid, Murcia, Valencia

2025-07-25

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

A Coruña, Badajoz, Barcelona, Cáceres, El Palmar, L'Hospitalet de Llobregat, Lleida, Madrid

2025-07-24

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244Acute Ischemic Stroke, Cerebral Stroke

DrugSovateltide

Pharmazz, Inc.

Phase 3

514

Badalona, Barcelona, Albacete, Madrid, El Palmar, Seville, Tarragona, A Coruña

2025-07-24

Recruiting

EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors

NCT07163325Advanced Solid Tumor (Phase 1)

Epics Therapeutics

Phase 1

Barcelona, Madrid, Santiago de Compostela

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

A Coruña, Elche, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Palma, Madrid, Valencia

2025-07-23

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)

DrugsEYLEA (aflibercept)·4D-150 IVT

4D Molecular Therapeutics

Phase 3

480

Santiago de Compostela, Barcelona, Seville

2025-07-22

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Badalona, Barcelona, Beiro, Córdoba, Galdakao, Huelva, Jaén, Las Palmas de Gran Canaria

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia

2025-07-21

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Barcelona, Donostia / San Sebastian, Santander, Pozuelo de Alarcón, Valencia, Madrid

2025-07-21

Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 1/2

140

Madrid, Barcelona

2025-07-20

Recruiting

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631Metastatic Colorectal Cancer

DrugsBNT314·Pumitamig·Bevacizumab

BioNTech SE

Phase 1/2

482

Barcelona, Madrid

2025-07-18

Recruiting

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385Familial Adenomatous Polyposis (FAP)

DrugERapa

Rapamycin Holdings Inc.

Phase 3

168

Barcelona, Inca, Madrid, Valencia

2025-07-18

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Barcelona, Bilbao

2025-07-18

Recruiting

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

NCT07015697Recurrent or Metastatic Solid Tumors

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 1

Barcelona, Madrid, Seville

2025-07-17

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia

2025-07-17

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia

2025-07-16

Recruiting

Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis

NCT06533852Decompensated Cirrhosis

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Phase 3

190

Barcelona, Madrid, Sabadell, Santander

2025-07-16

Recruiting

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis

DrugsUplizna·Inebilizumab·Blinatumomab

Amgen

Phase 2

220

Santander, Barcelona, Madrid

2025-07-16

Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494Early Alzheimer's Disease

Merck Sharp & Dohme LLC

Phase 2

340

Terrassa, Barcelona

2025-07-16

Recruiting

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

NCT07107230Advanced Stage Solid Tumors

DrugAmivantamab

Janssen Research & Development, LLC

Phase 1

400

Barcelona, Madrid

2025-07-15

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Badalona, Barakaldo, Pamplona, Barcelona, Madrid, Seville

2025-07-15

Recruiting

Body Composition Assessment and Monitoring in Inflammatory Bowel Disease

NCT07162701Body Composition Changes, Malnutrition

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2025-07-15

Active, closed

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Barcelona, Esplugues de Llobregat, Donostia / San Sebastian, Madrid, Málaga, Murcia

2025-07-14

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Seville, Sant Cugat del Vallès, Barcelona, Lleida, Pamplona, Madrid

2025-07-14

Recruiting

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515Acute Decompensated Heart Failure

DrugFurosemide

Reprieve Cardiovascular, Inc

Phase 3

400

Barcelona, Madrid, Valencia

2025-07-14

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474COVID-19 Infection

DrugsIbuzatrelvir·Veklury·Remdesivir

Pfizer

Phase 3

300

A Coruña, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante, Seville

2025-07-14

Recruiting

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

NCT06832722Shock, Cardiogenic

4TEEN4 Pharmaceuticals GmbH

Phase 1/2

A Coruña, Barcelona, Madrid

2025-07-13

Active, closed

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384HIV Infections

DrugsVH3810109·Fostemsavir

ViiV Healthcare

Phase 1

107

Pozuelo de Alarcón, Barcelona, Córdoba, La Laguna Santa Cruz, Madrid, Palma de Mallorca, Seville, Valencia

2025-07-10

Recruiting

The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis

NCT07168772Multiple Sclerosis

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2025-07-10

Active, closed

Support C Post-Market Registry

NCT06678490Coronary Arteriosclerosis

OrbusNeich

Observational

282

Barcelona, Lugo, Madrid, Murcia, Seville

2025-07-09

Recruiting

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

NCT07153445Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer

DrugsTecentriq·Paraplatin·Taxol·Atezolizumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Jerez de la Frontera, Girona, Granada, A Coruña

2025-07-08

Recruiting

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

NCT07076407Major Depressive Disorder

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

450

Barcelona, Palma de Mallorca

2025-07-08

Active, closed

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06991556Metastatic Hormone-sensitive Prostate Cancer

DrugsLuxdegalutamide·Abiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 2

168

Santander, Badajoz, Lugo, Barcelona, Córdoba

2025-07-07

Active, closed

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118Prostatic Cancer, Castration-Resistant

DrugsLuxdegalutamide·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

138

Granada, El Palmar, Barcelona, Seville

2025-07-03

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

Denia, Martorell, Terrassa, Pozuelo de Alarcón, Barcelona, Córdoba, Donosti-San Sebastián, Granada

2025-07-02

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida

2025-07-02

Recruiting

Fighting Addictions, Improving Lives: COmprehensive Drug Rehabilitation With Music

NCT07028983Substance Use Disorder (SUD)

NORCE Norwegian Research Centre AS

Not applicable

600

Barcelona, Girona

2025-07-01

Not yet open

OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs

NCT06929182Antiphospholipid Syndrome (APS), Direct Oral Anticoagulants (DOACs), Thrombotic and Bleeding Events, Safety

Central Hospital, Nancy, France

Observational

500

Barcelona

2025-07-01

Not yet open

The COMFORTage Project at Ace Alzheimer Center Barcelona

NCT07031167Alzheimer Disease, Mild Cognitive Impairment

Fundació ACE Institut Català de Neurociències Aplicades

Not applicable

100

Barcelona

2025-07-01

Recruiting

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)

NCT07067437Breast Neoplasms

National Institute of Oncology, Hungary

Not applicable

250

Barcelona, Pamplona, Valencia

2025-07-01

Recruiting

Feeling Safe Study

NCT07234708Schizophrenia and Schizophrenia Spectrum Psychosis

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

Barcelona

2025-07-01

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

2,400

L'Hospitalet de Llobregat, Bilbao, Salamanca, Jaén, Santiago de Compostela, Pozuelo de Alarcón, Valencia, Barcelona

2025-06-30

Recruiting

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

NCT06937931Cervical Dystonia

DrugCorabotase

Ipsen

Phase 2

132

Barcelona, Cadiz, Madrid, Seville

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis

DrugNizubaglustat

Azafaros B.V.

Phase 3

147

Barcelona, Madrid

2025-06-30

Active, closed

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1

DrugNizubaglustat

Azafaros B.V.

Phase 3

Barcelona, Madrid

2025-06-30

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

NCT07082725Niemann-Pick Type C Disease

DrugNizubaglustat

Azafaros B.V.

Phase 3

Barcelona, Madrid

2025-06-30

Recruiting

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

NCT06979375Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Granada, Girona, El Palmar, Barcelona, Denia, Las Palmas de Gran Canaria, Madrid, Majadahonda

2025-06-30

Recruiting

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma

DrugsCDK4/6i·Trastuzumab deruxtecan

MedSIR

Phase 2

200

Barcelona, Cáceres, Girona, Granada, Jaén, Madrid, Majadahonda, Murcia

2025-06-30

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

Active, closed

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

NCT06966453Breast Cancer, Breast Neoplasms

DrugDisitamab Vedotin

Pfizer

Phase 1/2

Barcelona, Madrid, Málaga, Valencia, Granada

2025-06-30

Active, closed

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT06794554Chronic Pulmonary Aspergillosis

Mundipharma Research Limited

Phase 2

Barcelona, Madrid, Martorell, Valencia

2025-06-30

Recruiting

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862Duchenne Muscular Dystrophy (DMD)

DrugENTR-601-44

Entrada Therapeutics, Inc.

Phase 1/2

Barcelona

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Alicante, Badalona, Barcelona, Cadiz, Córdoba, Granada, Granollers, Madrid

2025-06-27

Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration

DrugTYRA-300

Tyra Biosciences, Inc

Phase 2

Barcelona, Madrid, Santander

2025-06-27

Recruiting

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis

NCT06315010NSCLC, Brain Metastases, ROS1 Gene Rearrangement

DrugRepotrectinib

MedSIR

Phase 2

Elche, Barcelona, Girona, Madrid, Reus, Alicante, Barakaldo, León

2025-06-27

Recruiting

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362Heart Failure

DrugCDR132L

Novo Nordisk A/S

Phase 2

200

Granada, El Palmar, Barcelona, Las Palmas de Gran Canaria, Madrid, Valencia

2025-06-27

Recruiting

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

NCT07483827C3 Glomerulopathy (C3G), Healthy Adult Participants

eleva GmbH

Phase 1

Barcelona, Madrid, Pamplona, Seville

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

NCT06409936CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia

DrugsAsciminib·Nilotinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

160

Barcelona, Bilbao, Girona, Granada, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2025-06-26

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña

2025-06-25

Active, closed

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919Allergy, Peanut Allergy

DBV Technologies

Phase 3

480

Barcelona, Madrid, Málaga, Santiago de Compostela

2025-06-24

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-06-23

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225Hidradenitis Suppurativa

Incyte Corporation

Phase 3

580

Alicante, Badalona, Barcelona, Madrid

2025-06-23

Active, closed

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 1/2

Barcelona, Madrid

2025-06-20

Active, closed

A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

NCT06736990Idiopathic Pulmonary Fibrosis

Calluna Pharma AS

Phase 2

150

Barcelona, Santander, Santiago de Compostela

2025-06-20

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Pozuelo de Alarcón, Marbella, Alzira, Barcelona, Benalmádena, Ferrol, GaldakaoVizcaya, Madrid

2025-06-20

Recruiting

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta

W.L.Gore & Associates

Observational

1,500

Barcelona

2025-06-19

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Santiago de Compostela, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid, Valencia

2025-06-19

Active, closed

Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)

NCT06991322Coronary Microvascular Dysfunction, Coronary Microvascular Disease

VahatiCor, Inc.

Not applicable

Barcelona

2025-06-18

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

Incyte Corporation

Phase 3

159

Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela

2025-06-17

Active, closed

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771Homozygous Familial Hypercholesterolemia

DrugZodasiran

Arrowhead Pharmaceuticals

Phase 3

Barcelona, Córdoba, Madrid

2025-06-17

Recruiting

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

Almería, Barcelona, Seville

2025-06-14

Recruiting

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

NCT06789913PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation

DrugRLY-2608

Relay Therapeutics, Inc.

Phase 2

277

A Coruña, Barcelona, Madrid

2025-06-13

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features

DrugKarXT

Bristol-Myers Squibb

Phase 3

274

Barcelona, Bilbao

2025-06-13

Active, closed

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

NCT07029555Rheumatoid Arthritis

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Santiago Compostela, Barcelona

2025-06-12

Recruiting

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

NCT06990880Neoplasms, Prostate

GlaxoSmithKline

Phase 1/2

Badajoz, Barcelona, Madrid, Málaga, Pozuelo de AlarcOn Madr

2025-06-12

Recruiting

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

DrugsAmino acid·Lanreotide·Octreotide LAR·Lutathera

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

166

Barcelona, L'Hospitalet de Llobregat, Burgos, Granada, Madrid, Oviedo, Seville, Valencia

2025-06-12

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211Hidradenitis Suppurativa

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

Incyte Corporation

Phase 3

573

Barcelona, Esplugues de Llobregat, Granada, Granollers, Las Palmas de Gran Canaria, Madrid, Manises, Santiago de Compostela

2025-06-12

Recruiting

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

451

Barcelona, HebrOn, Madrid, Pamplona, Santander, Zaragoza

2025-06-11

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Barcelona, LHospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Seville

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Barcelona, Córdoba, Donostia / San Sebastian, Girona, Madrid, Valencia

2025-06-10

Recruiting

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1

DrugDel-brax

Avidity Biosciences, Inc.

Phase 3

200

Barcelona, San Sebastián, Valencia

2025-06-10

Active, closed

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

NCT06906822Melanoma

DrugsEnfortumab Vedotin·Pembrolizumab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Badalona, Barcelona, Santander, Madrid, Murcia, Seville, Valencia

2025-06-10

Active, closed

REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

NCT06914609Angelman Syndrome

DrugObudanersen

Ionis Pharmaceuticals, Inc.

Phase 3

156

Barcelona, Sabadell

2025-06-10

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136Heterozygous Familial Hypercholesterolaemia

DrugAZD0780

AstraZeneca

Phase 3

473

A Coruña, Barcelona, Córdoba, Reus, Seville

2025-06-10

Recruiting

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

NCT07516964Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

Meyer Children's Hospital IRCCS

Not applicable

Barcelona

2025-06-10

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Manises, Barcelona, Granada

2025-06-09

Recruiting

Chronic Insomnia in Non-Cancer Pain Patients

NCT07057232Chronic Non-cancer Pain, Insomnia

Germans Trias i Pujol Hospital

Observational

385

Badalona, Barcelona, Girona, Hospitalet Del Llobregat, Lleida, Sant Joan Despí, Tarragona, Terrassa

2025-06-09

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

A Coruña, Badalona, Barcelona, El Palmar, Girona, Huelva, Jerez de la Frontera, L'Hospitalet de Llobregat

2025-06-09

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Barcelona, L'Hospitalet de Llobregat, Granada, Madrid, Seville, Valencia

2025-06-09

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia

2025-06-05

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

A Coruña, Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón

2025-06-04

Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders

DrugSepofarsen

Laboratoires Thea

Phase 3

Barcelona

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia

2025-06-04

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-06-04

Recruiting

Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study

NCT07188220Metabolic Dysfunction Associated Steatohepatitis (MASH)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

Barcelona

2025-06-03

Active, closed

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C

DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir

Atea Pharmaceuticals, Inc.

Phase 3

880

Santander, Málaga, Vigo, Barcelona

2025-06-02

Recruiting

Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study

NCT05881798Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism

Cook Research Incorporated

Observational

Barcelona, Córdoba, Sabadell

2025-06-02

Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627Venous Leg Ulcer (VLU)

DrugEscharEx

MediWound Ltd

Phase 3

216

Barcelona, Madrid, Pamplona

2025-06-01

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

L'Hospitalet de Llobregat, Oviedo, Barcelona, Madrid, Salamanca

2025-05-30

Recruiting

Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis

NCT07236970Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH

Alejandro Cruz Utrilla

Observational

350

Granada, Santander, Barcelona, Madrid

2025-05-30

Recruiting

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

NCT06887088Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases

DrugsFianlimab·Binimetinib·Encorafenib·Cemiplimab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Barcelona, Burgos, Santander, Cáceres, Donostia / San Sebastian, Madrid, Majadahonda

2025-05-29

Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Barcelona, Madrid

2025-05-29

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Badalona, Jaén, El Palmar, Pamplona, Seville, Barcelona, Madrid, Valencia

2025-05-28

Active, closed

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373VEXAS, VEXAS Syndrome

DrugPacritinib

Swedish Orphan Biovitrum

Phase 2

156

Barcelona, L'Hospitalet de Llobregat, Salamanca

2025-05-28

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2025-05-28

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

A Coruña, Barcelona, Córdoba, Madrid, Santiago(A Coruña), Seville

2025-05-28

Active, closed

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria

Blueprint Medicines Corporation

Phase 2

105

Barcelona, Málaga

2025-05-28

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Barcelona, Córdoba, Madrid

2025-05-27

Recruiting

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT06941272Malignant Neoplasm

DrugPatritumab deruxtecan

Merck Sharp & Dohme LLC

Phase 1/2

Esplugues de Llobregat, Barcelona, Madrid

2025-05-26

Recruiting

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

NCT05974774Prostate Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

1,600

Barcelona, Madrid, Majadahonda

2025-05-23

Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck

DrugPembrolizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

200

Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-23

Active, closed

The RECOVERY Study: Using Supersaturated Oxygen Therapy To Treat Small Vessel Blockages After a Heart Attack

NCT07000266Anterior STEMI

Fundacio Privada Mon Clinic Barcelona

Not applicable

Barcelona

2025-05-23

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Elche, San Cugat Del Valles Barcelona, Madrid, Navarra, A Coruña, Barcelona, El Palmar, Lleida

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

L'Hospitalet de Llobregat, Girona, Barcelona, Córdoba, Madrid, Valencia

2025-05-22

Active, closed

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590Idiopathic Hypersomnia

DrugALKS 2680

Alkermes, Inc.

Phase 2

126

Barcelona, Madrid

2025-05-22

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Santiago de Compostela, Badalona, Barcelona, Santander, Cáceres, Lugo, Girona, Madrid

2025-05-22

Recruiting

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 2

Barcelona, Pamplona, Alicante, Madrid

2025-05-22

Active, closed

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830Hemophilia A

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

252

Salamanca, A Coruña, Barcelona, Málaga, Palma de Mallorca, Zaragoza

2025-05-21

Active, closed

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

NCT06966479Severe Asthma

DrugVerekitug

Upstream Bio Inc.

Phase 2

396

Barcelona, Madrid

2025-05-21

Active, closed

A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)

NCT06962852Cystic Fibrosis

Boehringer Ingelheim

Phase 1/2

Barcelona

2025-05-20

Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

4,200

Barcelona, Madrid, Sanlúcar de Barrameda, Torrejón de Ardoz, Valencia, Villamartín

2025-05-20

Not yet open

Cortical Effects of Peripheral Proprioceptive Stimulation on the Motor Evoked Potentials of the Limbs

NCT06936579Healthy Subjects

Facultat de ciencies de la Salut Universitat Ramon Llull

Not applicable

Barcelona

2025-05-20

Recruiting

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

NCT06991946Metastatic Breast Cancer

SOLTI Breast Cancer Research Group

Observational

300

Barcelona

2025-05-20

Recruiting

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

NCT06711887Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

348

Barcelona

2025-05-19

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Barcelona, Madrid, Salamanca, Seville

2025-05-19

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Badajoz, Barakaldo, Barcelona, Cadiz, Córdoba, Granada, Madrid, Málaga

2025-05-19

Active, closed

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

NCT06898957Small Cell Lung Cancer

DrugsTam-Peli·Tarlatamab·Durvalumab

Amgen

Phase 1

Barcelona, Majadahonda, Madrid

2025-05-16

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia

2025-05-15

Recruiting

EFESO: Study on Juvenile Onset Eosinophilic Fasciitis

NCT07348263Eosinophilic Fasciitis

Meyer Children's Hospital IRCCS

Observational

Barcelona

2025-05-15

Recruiting

Evaluation of an Integrated Home Care Model

NCT07408882Older Adults (70 or More) Living at Home With Health and Social Complexity

Parc Sanitari Pere Virgili

Not applicable

1,000

Barcelona, Girona, Olot, Vic

2025-05-15

Not yet open

Multicomponent FIBROWALK Therapy Plus Unified Protocol for Emotional Regulation in Individuals With Fibromyalgia

NCT06906991Fibromyalgia (FM)

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

182

Barcelona

2025-05-15

Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine

DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab

AstraZeneca

Phase 2

150

Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Santiago de Compostela

2025-05-15

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

A Coruña, Barcelona, Madrid, Sabadell, Seville

2025-05-14

Active, closed

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852Head and Neck Squamous Cell Carcinoma

DrugsBI 770371·Cetuximab·Pembrolizumab

Boehringer Ingelheim

Phase 1

Barcelona

2025-05-14

Recruiting

Digital Solutions for bEtter cAre

NCT07416513Cancer Diagnosis

European Institute of Oncology

Not applicable

200

Barcelona

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Santander, Santiago de Compostela, Majadahonda Madrid, Madrid, Barcelona, Córdoba, Lugo, Seville

2025-05-13

By invitation

The Effect of Digital Markers in the Self-management of Depressive Symptoms

NCT06919133Depression - Major Depressive Disorder, Mental Distress

Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Not applicable

660

Barcelona

2025-05-13

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

587

A Coruña, Barcelona, Huelva, Majadahonda, Palma de Mallorca, Salamanca

2025-05-12

Active, closed

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

465

Badajoz, Badalona, Barcelona, Madrid, Seville

2025-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Palma, Santander, Barcelona, Madrid, Seville, Toledo

2025-05-12

Recruiting

FB-CT2 Includes Two Prospective, Multi-centre Studies With a Medical Device in Hospital Settings: a Randomized, Dual-arm, Open-label Pilot Study in Spain, Followed by a Single-arm, Non-randomized, Open-label International Pivotal Study

NCT06968364Threatened Preterm Labor

Ultrasound-Innovation Medtech, S.L.

Not applicable

457

A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-10

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

Viladecans, Barcelona, A Coruña, Alcorcón, Getafe, Cáceres, Girona, Madrid

2025-05-08

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Barcelona, Madrid, Santander

2025-05-06

Active, closed

FARAPULSE Workflow Assessment Registry

NCT06656884Atrial Fibrillation (AF)

Boston Scientific Corporation

Observational

524

Barcelona, El Palmar, Pamplona, Santa Cruz de Tenerife

2025-05-06

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Salamanca, Barcelona, L'Hospitalet de Llobregat, Madrid, Valencia

2025-05-06

Recruiting

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

DrugsTAK-881·Phesgo

Takeda

Phase 3

Barcelona, Valencia

2025-05-06

Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246Intracerebral Hemorrhage

DrugRecombinant Factor VIIa

Joseph Broderick, MD

Phase 3

350

Badalona, Horta, L'Hospitalet de Llobregat, Barcelona, Girona, Lleida, Valladolid

2025-05-06

Active, closed

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

NCT06799247Myasthaenia Gravis

Cartesian Therapeutics

Phase 3

128

Barcelona, Madrid

2025-05-06

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)

DrugsCetuximab·Docetaxel

Revolution Medicines, Inc.

Phase 3

590

A Coruña, Barcelona, Fuencarral-El Pardo, Madrid

2025-05-06

Recruiting

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

NCT06652438Acute Myeloid Leukemia, Adult

DrugRevumenib

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3

448

Alicante, Barcelona, Girona, Lleida, Madrid, Palma de Mallorca, Tarragona, Valencia

2025-05-05

Active, closed

Multimodal Training With Immersive Virtual Reality to Improve the Cognitive Health and Emotional Well-being of Older Women Living Alone

NCT06956794Social Isolation in Older Adults, Poverty

Consorci Sanitari de Terrassa

Not applicable

Barcelona, Terrassa

2025-05-05

Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805Idiopathic Pulmonary Fibrosis

Mediar Therapeutics

Phase 2

164

Barcelona, Lugo, Madrid, Santander

2025-05-05

Active, closed

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity

DrugsRO7204239·Tirzepatide

Hoffmann-La Roche

Phase 2

285

Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga

2025-05-05

Recruiting

Effectiveness of a Telerehabilitation Program for Improving Sexual Function and Reducing Pain in Menopausal Women

NCT06710002Menopause, Genitourinary Syndrome of Menopause, Dyspareunia

Instituto Médico Tecnológico SL

Not applicable

Barcelona

2025-05-05

Recruiting

2024 NewAnescat Register

NCT06792773Anesthesia

Consorci Sanitari de Terrassa

Observational

13,634

Barcelona

2025-05-04

Recruiting

Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41

NCT07504913Stomach Neoplasms, Validation Study

Parc de Salut Mar

Observational

505

Badalona, Barcelona, L'Hospitalet de Llobregat, Puerto Real, Logroño, Lleida

2025-05-03

Recruiting

Treatment of Rumination

NCT06971354Rumination Syndrome

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

Barcelona

2025-05-02

Recruiting

Study of the Effect of Peripheral Somatosensory Stimulation on the Functionality of Patients With Cerebral Palsy and Reduced Mobility

NCT06951568Cerebral Palsy

Facultat de ciencies de la Salut Universitat Ramon Llull

Not applicable

Barcelona

2025-05-02

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Barcelona, Córdoba, Málaga, Seville, Torrejón de Ardoz, Valencia

2025-05-02

Recruiting

Identity-Based Transdiagnostic Therapy for Young People With Anxiety and Depression

NCT06384196Depression, Anxiety

University of Barcelona

Not applicable

138

Badalona, Barcelona

2025-05-02

By invitation

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

NCT07055607Obesity

DrugsWegovy·Semaglutide

Novo Nordisk A/S

Observational

1,250

Barcelona, Cartagena, Castilleja de la Cuesta, El Palmar (Murcia), Ferrol, Getafe (Madrid), La Cuesta (Santa Cruz de Tenerife), Las Palmas de Gran Canaria

2025-05-01

Recruiting

Creation of Arteriovenous Fistulas for Hemodialysis Using the End-to-side Anastomotic Technique vs. Piggyback.

NCT06997042Chronic Kidney Disease Requiring Hemodialysis

Hospital Clinic of Barcelona

Not applicable

130

Barcelona

2025-05-01

Recruiting

Validation of a Questionnaire to Measure Cough Severity

NCT06669897Cough

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

100

Badalona, L'Hospitalet de Llobregat, Sabadell, Barcelona

2025-05-01

By invitation

ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients

NCT07070284Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation

Joan Sabater-Riera

Observational

500

Seville, L'Hospitalet de Llobregat, Barcelona, Sabadell, Donostia / San Sebastian

2025-05-01

Not yet open

Effects of Peripheral Somatosensory Stimulation Via Mechanical Pressure on Lower Limb Muscle Strength in Healthy Subjects.

NCT06936020Healthy Volunteers

Facultat de ciencies de la Salut Universitat Ramon Llull

Not applicable

Barcelona

2025-05

Not yet open

Effects of Peripheral Somatosensory Stimulation Through Mechanical Pressure on Lower Limb Muscle Strength in Stroke Survivors

NCT06958185Stroke

Pedro Victor López Plaza

Not applicable

Barcelona

2025-05

Not yet open

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

NCT06852625Kidney Transplant Rejection

Fundacion Clinic per a la Recerca Biomédica

Phase 1

Badalona, Barcelona, L'Hospitalet de Llobregat, Zaragoza

2025-05

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCT06948435Hypertension, Overweight or Obesity

Eli Lilly and Company

Phase 3

487

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Santiago Compostela, Pamplona, Castilleja de la Cuesta, A Coruña, Barcelona, Córdoba, Huelva, Las Palmas GC

2025-04-30

Active, closed

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422Hypertension

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Eli Lilly and Company

Phase 3

974

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Recruiting

NCT06884618Neoplasms

Hoffmann-La Roche

Phase 1

405

Pamplona, Barcelona, Madrid

2025-04-30

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530Hypertension